Search research articles
Contact Us
Filters
Showing results (251-260 of 525) with videos related to
Page
of 53
Sort By:
Plos Pathogens
|
May 11, 2018
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins
Torben Schiffner, Jesper Pallesen, Rebecca A Russell, et al.
Scientific Reports
|
May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers
Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Viruses
|
December 23, 2022
Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques
Bapi Pahar, Wayne Gray, Marissa Fahlberg, et al.
Vaccine
|
October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
Paul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Vaccine
|
September 7, 2023
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US
Hong-Van Tieu, Shelly Karuna, Yunda Huang, et al.
Journal of Virology
|
July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques
Smita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.
Plos Pathogens
|
March 15, 2021
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, et al.
Viruses
|
September 28, 2024
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
Ying Huang, Shomoita Alam, Erica Andersen-Nissen, et al.
Plos Pathogens
|
June 20, 2024
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Camille N Pierre, Lily E Adams, Jaclyn S Higgins, et al.
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
Page
of 53
Search research articles
Search
Showing results (251-260 of 525) with videos related to
Sort By:
Page
of 53
Plos Pathogens
|
May 11, 2018
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins
Torben Schiffner, Jesper Pallesen, Rebecca A Russell, et al.
Scientific Reports
|
May 29, 2026
CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers
Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Viruses
|
December 23, 2022
Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques
Bapi Pahar, Wayne Gray, Marissa Fahlberg, et al.
Vaccine
|
October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
Paul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Vaccine
|
September 7, 2023
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US
Hong-Van Tieu, Shelly Karuna, Yunda Huang, et al.
Journal of Virology
|
July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques
Smita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.
Plos Pathogens
|
March 15, 2021
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, et al.
Viruses
|
September 28, 2024
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
Ying Huang, Shomoita Alam, Erica Andersen-Nissen, et al.
Plos Pathogens
|
June 20, 2024
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Camille N Pierre, Lily E Adams, Jaclyn S Higgins, et al.
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
Page
of 53